Published :
Tables : 60
Figures : 50
Category : Healthcare
No. of Pages : 222
Report Code : HC-U3359
Medulloblastoma Market Introduction: The increase in the number of cancer patients across the world and the rising awareness among people regarding cancer and its treatment are some of the primary factors which has assisted in the growth of the market. As per the data provided by the American Brain Tumor Association, over four hundred patients, mainly children, are diagnosed with medulloblastoma every year, with males being more prone to the disease than women. It is the most found malignant brain tumor in children of age four and younger and the second most in children between the age range of five to fourteen years. The report further states that over one-fourth of all the adults diagnosed with medulloblastoma in the United States are of the age twenty to forty-four years. These factors are responsible for increase of the medulloblastoma market share of the United States. Market Segmentation: By Type • Classic medulloblastoma • Desmoplastic nodular medulloblastoma • Medulloblastoma with extensive nodularity • Large cell medulloblastoma • Anaplastic medulloblastoma • Melanotic medulloblastoma • Medullomyoblastoma By Treatment • Surgery • Radiation therapy • Clinical trials • Chemotherapy By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa The global market is segmented as type, treatment and region. The type segment is further classified as classic medulloblastoma, desmoplastic nodular medulloblastoma, medulloblastoma with extensive nodularity, large cell medulloblastoma, anaplastic medulloblastoma, melanotic medulloblastoma and medullomyoblastoma. The treatment segment id further divided into surgery, radiation therapy, clinical trials and chemotherapy. Competitive Analysis: The top market players included are Bristol-Myers Squibb Co., Bayer AG, Delmar Pharmaceuticals Inc., IMPACT Therapeutics, Ignyta Inc., Lipocure Ltd., MacroGenics Inc., Newlink Genetics Corp., Ono Pharmaceutical Co. Ltd., Progenics Pharmaceuticals Inc. FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the global medulloblastoma market by type, by treatment and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Medulloblastoma Market Introduction:
The increase in the number of cancer patients across the world and the rising awareness among people regarding cancer and its treatment are some of the primary factors which has assisted in the growth of the market. As per the data provided by the American Brain Tumor Association, over four hundred patients, mainly children, are diagnosed with medulloblastoma every year, with males being more prone to the disease than women. It is the most found malignant brain tumor in children of age four and younger and the second most in children between the age range of five to fourteen years. The report further states that over one-fourth of all the adults diagnosed with medulloblastoma in the United States are of the age twenty to forty-four years. These factors are responsible for increase of the medulloblastoma market share of the United States.
Market Segmentation:
By Type • Classic medulloblastoma • Desmoplastic nodular medulloblastoma • Medulloblastoma with extensive nodularity • Large cell medulloblastoma • Anaplastic medulloblastoma • Melanotic medulloblastoma • Medullomyoblastoma By Treatment • Surgery • Radiation therapy • Clinical trials • Chemotherapy By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa
The global market is segmented as type, treatment and region. The type segment is further classified as classic medulloblastoma, desmoplastic nodular medulloblastoma, medulloblastoma with extensive nodularity, large cell medulloblastoma, anaplastic medulloblastoma, melanotic medulloblastoma and medullomyoblastoma. The treatment segment id further divided into surgery, radiation therapy, clinical trials and chemotherapy.
Competitive Analysis:
The top market players included are Bristol-Myers Squibb Co., Bayer AG, Delmar Pharmaceuticals Inc., IMPACT Therapeutics, Ignyta Inc., Lipocure Ltd., MacroGenics Inc., Newlink Genetics Corp., Ono Pharmaceutical Co. Ltd., Progenics Pharmaceuticals Inc.
FutureWise Key Takeaways:
• Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth
Objectives of the Study:
• To provide with an exhaustive analysis on the global medulloblastoma market by type, by treatment and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Global Medulloblastoma Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Global Medulloblastoma Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Medulloblastoma Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Medulloblastoma Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Medulloblastoma Market, By Type Historical Analysis and Forecast 2020-2027 (USD Million) 7.1. Classic medulloblastoma 7.2. Desmoplastic nodular medulloblastoma 7.3. Medulloblastoma with extensive nodularity 7.4. Large cell medulloblastoma 7.5. Anaplastic medulloblastoma 7.6. Melanotic medulloblastoma 7.7. Medullomyoblastoma 8. Global Medulloblastoma Market, By Treatment Historical Analysis and Forecast 2020-2027 (USD Million) 8.1. Surgery 8.2. Radiation therapy 8.3. Clinical trials 8.4. Chemotherapy 9. North America Market Analysis 2012–2019 and Forecast 2020–2027 (USD Million) 9.1. Introduction 9.2. Historical Market Size (USD Million) Analysis By Country, 2012-2019 9.2.1. U.S.A 9.2.2. Canada 9.2.3. Mexico 9.3. Market Size (USD Million) Forecast for North America 2020-2027 10. Latin America Market Analysis 2012–2019 and Forecast 2020–2027 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2012-2019 10.2.1. Brazil 10.2.2. Venezuela 10.2.3. Argentina 10.2.4. Rest of Latin America 10.3. Market Size (USD Million) Forecast for Latin America 2020-2027 11. Europe Market Analysis 2012–2019 and Forecast 2020–2027 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2012-2019 11.2.1. Germany 11.2.2. U.K 11.2.3. France 11.2.4. Italy 11.2.5. Spain 11.2.6. Russia 11.2.7. Poland 11.2.8. Rest of Europe 11.3. Market Size (USD Million) Forecast for Europe 2020-2027 12. Asia Pacific Market Analysis 2012–2019 and Forecast 2020–2027 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2012-2019 12.2.1. Japan 12.2.2. China 12.2.3. India 12.2.4. Australia and New Zealand 12.2.5. ASEAN 12.2.6. Rest of Asia Pacific 12.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027 13. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 13.2.1. Saudi Arabia 13.2.2. UAE 13.2.3. South Africa 13.2.4. Egypt 13.3. Market Size (USD Million) Forecast for MEA 2020-2027 14. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts) 14.1. Bristol-Myers Squibb Co. 14.1.1. Company Overview 14.1.2. Product Portfolio 14.1.3. SWOT Analysis 14.1.4. Financial Overview 14.1.5. Strategic Overview 14.2. Bayer AG 14.2.1. Company Overview 14.2.2. Product Portfolio 14.2.3. SWOT Analysis 14.2.4. Financial Overview 14.2.5. Strategic Overview 14.3. Delmar Pharmaceuticals Inc. 14.3.1. Company Overview 14.3.2. Product Portfolio 14.3.3. SWOT Analysis 14.3.4. Financial Overview 14.3.5. Strategic Overview 14.4. IMPACT Therapeutics 14.4.1. Company Overview 14.4.2. Product Portfolio 14.4.3. SWOT Analysis 14.4.4. Financial Overview 14.4.5. Strategic Overview 14.5. Ignyta Inc. 14.5.1. Company Overview 14.5.2. Product Portfolio 14.5.3. SWOT Analysis 14.5.4. Financial Overview 14.5.5. Strategic Overview 14.6. Lipocure Ltd. 14.6.1. Company Overview 14.6.2. Product Portfolio 14.6.3. SWOT Analysis 14.6.4. Financial Overview 14.6.5. Strategic Overview 14.7. MacroGenics Inc. 14.7.1. Company Overview 14.7.2. Product Portfolio 14.7.3. SWOT Analysis 14.7.4. Financial Overview 14.7.5. Strategic Overview 14.8. Newlink Genetics Corp. 14.8.1. Company Overview 14.8.2. Product Portfolio 14.8.3. SWOT Analysis 14.8.4. Financial Overview 14.8.5. Strategic Overview 14.9. Ono Pharmaceutical Co. Ltd. 14.9.1. Company Overview 14.9.2. Product Portfolio 14.9.3. SWOT Analysis 14.9.4. Financial Overview 14.9.5. Strategic Overview 14.10. Progenics Pharmaceuticals Inc. 14.10.1. Company Overview 14.10.2. Product Portfolio 14.10.3. SWOT Analysis 14.10.4. Financial Overview 14.10.5. Strategic Overview 15. Impact of COVID-19 15.1. Positive influence on the healthcare industry 15.2. The financial disruption of the manufacturing sector 15.3. Impact of COVID-19 on emerging companies 15.4. Significant mandates in the healthcare regulations initiated by administrations 15.5. The overall economic slowdown of the developing and developed nations 16. Competitive Intelligence and Competitive Matrix 16.1 Competitive Intelligence 16.2 Competitive Matrix 17. Major Deals and Strategic Alliances Analysis 17.1 Joint ventures 17.2 Mergers and acquisitions 17.3 Licensing and partnerships 17.4 Technology Collaborations 17.5 Strategic Divestments 17.6 Market Entry Strategies 18. Relevant Case Studies and Latest News Updates 19. Research Sources and List of Primary Contacts of this Study 20. Key Market Takeaway Points from the Market Analysts at Future Market Analytics
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics